Log In
Print
BCIQ
Print
Print this Print this
 

Emend, Ivemend, Proemend, fosaprepitant dimeglumine, fosaprepitant meglumine (MK-0517, ONO-7847)

Also known as: Emend For Injection

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionInjectable formulation of the selective neurokinin 1 (NK1) receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients ages 6 months-17 years; Treat digestive symptoms resulting from the administration of antineoplastic agents.
Regulatory Designation

Partner

Ono Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today